FMP
Vaxcyte, Inc.
PCVX
NASDAQ
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
74.37 USD
1.35 (1.82%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
159.74M
305.44M
437.86M
582.02M
714.73M
1.05B
1.56B
2.3B
3.39B
5B
Revenue %
-
91.21
43.35
32.93
22.8
47.57
47.57
47.57
47.57
Ebitda
1.51M
106.37M
143.57M
221.51M
233.41M
293.81M
433.57M
639.83M
944.22M
1.39B
Ebitda %
0.95
34.82
32.79
38.06
32.66
27.86
27.86
27.86
27.86
Ebit
-8.72M
87.53M
120.19M
197.15M
209.3M
240.06M
354.27M
522.8M
771.5M
1.14B
Ebit %
-5.46
28.66
27.45
33.87
29.28
22.76
22.76
22.76
22.76
Depreciation
10.24M
18.84M
23.39M
24.36M
24.11M
53.74M
79.31M
117.04M
172.71M
254.88M
Depreciation %
6.41
6.17
5.34
4.19
3.37
5.1
5.1
5.1
5.1
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)
